Warp, interesting post as usual from Watsonhelper. He obviously has a science background and certainly knows the lingo. Whether or not he is spot on, who knows. But I think he has highlighted a couple of axiomatic truths re. AMBS current situation. First, that there are intense negotiations underway revolving around a LYMPRO partnership, and that the potential of MANF to be a blockbuster drug is beginning to catch the attention of some serious players. Secondly, that Gerald is at a key juncture with his investors as to his credibility, and that failure to deliver substantive data or information to assure shareholders prior to the Sept. 22 meeting would be a serious mistake, and Gerald and the BOD and BOA are all well aware of this. In addition to this the 8k detailing of increase spending on salaries and benefits for new hires says volumes about what is coming up. Patience at this juncture is so difficult, but sure looks like it will be well worth the wait. Thanks for posting!